Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Himmel

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Nucleic Acids Research|August 5, 2008
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug designJoseph D Bauman, Kalyan Das, William C Ho, et al.
Journal of Medicinal Chemistry|May 17, 2011
Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease HSuhman Chung, Daniel M Himmel, Jian-Kang Jiang, et al.
Structure (London, England : 1993)|December 17, 2009
Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active siteDaniel M Himmel, Karen A Maegley, Tom A Pauly, et al.
Journal of Pharmacological and Toxicological Methods|April 1, 2019
Variability of non-clinical behavioral CNS safety assessment: An intercompany comparisonH M Himmel, , A Delaunois, et al.
Journal of Medicinal Chemistry|November 24, 2005
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strainsDaniel M Himmel, Kalyan Das, Arthur D Clark, et al.
Journal of Medicinal Chemistry|March 18, 2005
4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strainsAbdellah Benjahad, Martine Croisy, Claude Monneret, et al.
ACS Chemical Biology|December 23, 2006
HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel siteDaniel M Himmel, Stefan G Sarafianos, Sanjeewa Dharmasena, et al.
Scientific Reports|March 30, 2020
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cellsJames Kramer, Herbert M Himmel, Anders Lindqvist, et al.
Scientific Reports|July 16, 2020
Publisher Correction: Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cellsJames Kramer, Herbert M Himmel, Anders Lindqvist, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Nucleic Acids Research|August 5, 2008
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug designJoseph D Bauman, Kalyan Das, William C Ho, et al.
Journal of Medicinal Chemistry|May 17, 2011
Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease HSuhman Chung, Daniel M Himmel, Jian-Kang Jiang, et al.
Structure (London, England : 1993)|December 17, 2009
Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active siteDaniel M Himmel, Karen A Maegley, Tom A Pauly, et al.
Journal of Pharmacological and Toxicological Methods|April 1, 2019
Variability of non-clinical behavioral CNS safety assessment: An intercompany comparisonH M Himmel, , A Delaunois, et al.
Journal of Medicinal Chemistry|November 24, 2005
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strainsDaniel M Himmel, Kalyan Das, Arthur D Clark, et al.
Journal of Medicinal Chemistry|March 18, 2005
4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strainsAbdellah Benjahad, Martine Croisy, Claude Monneret, et al.
ACS Chemical Biology|December 23, 2006
HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel siteDaniel M Himmel, Stefan G Sarafianos, Sanjeewa Dharmasena, et al.
Scientific Reports|March 30, 2020
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cellsJames Kramer, Herbert M Himmel, Anders Lindqvist, et al.
Scientific Reports|July 16, 2020
Publisher Correction: Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cellsJames Kramer, Herbert M Himmel, Anders Lindqvist, et al.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Pageof 8